Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
21 Cards in this Set
- Front
- Back
|
amount of drug in body/_______ = Vd
|
plasma drug concentration (note: Vd is Volume of Distribution)
|
|
|
rate of elimination of drug/[plasma drug] = ?
|
CL (Clearance)
|
|
|
(.7)(Vd)/CL = ?
|
T 1/2
|
|
|
A drug infused at a constant rate reaches about 94% of steady state after _______ t 1/2s.
|
4
|
|
|
A loading dose is calculated using this formula.
|
(Cp)(Vd)/F (note: Cp = target plasma concentration, and F = bioavailability)
|
|
|
A maintenance dose is calculated using this formula.
|
(Cp)(CL)/F
|
|
|
Rate of elimination is proportional to _______ ______ in 1st order elimination.
|
drug concentration
|
|
|
In the case of EtOH, which is elimated by _____ order elimination, a constant amount of drug is eliminated per unit time.
|
zero
|
|
|
Phase ____ (I or II) reactions yield slightly polar metabolites that are often _____ (active or inactive)
|
I, active
|
|
|
Phase ____ (I or II) reactions yield very polar metabolites that are often _____ (active or inactive) and are excreted by the _______.
|
II, inactive, kidney
|
|
|
Phase II reactions are often of this type.
|
conjugation
|
|
|
Cytochrome P-450 is involved in _____ phase (I or II) reactions.
|
I
|
|
|
A patent lasts for _____ years after filing for application.
|
20
|
|
|
How many phases are there in drug development?
|
4
|
|
|
Drugs are first tested in patients in phase _____ of clinical testing, pharmacokinetic safety is determined in phase ______ of clinical testing, double blind tests are done in phase ____ and post-market surveillance is done in phase _____.
|
2,1,3,4
|
|
|
In a dose response curve, a competitive antagonist shifts the curve _____, while a non-competitive antagonist shifts the curve ______.
|
right, down
|
|
|
What pharmacologic relationship would determine the existence of spare receptors?
|
EC50 < Kd
|
|
|
What does it mean if EC50 and Kd are equal?
|
The system does not have spare receptors
|
|
|
A partial agonist acts on the same receptor system as a full agonist? T/F
|
TRUE
|
|
|
What's the main difference between a partial agonist and a full agonist?
|
A partial agonist has a lower maximal efficacy.
|
|
|
Is a partial agonist less potent than a full agonist?
|
Not necessarily. It can be less, more or equally potent as a full agonist.
|
